[Pharmacokinetics and metabolism of anthracyclines in man].
Jacques Robert
Abstract
Jacques Robert
Abstract
Although they differ only slightly from each other, the various anthracyclines have their own metabolic pathways and pharmacokinetic parameters. Doxorubicin and daunorubicin have a similar reduced metabolite which reaches low plasma levels in the case of doxorubicin, but is predominant in the case of daunorubicin: daunorubicinol. Aglycones are only formed in large quantities from aclarubicin: aklavinone. The plasma decay of doxorubicin levels is triphasic, with successive half-lives of 5 min, 1 h and 30 h. Unchanged daunorubicin is eliminated more rapidly from plasma, but its metabolite is eliminated more slowly. New anthracyclines such as pirarubicin are characterized by a large volume of distribution, suggesting a higher tissue fixation. These pharmacokinetic data must be kept in mind for the design of new protocols which are aimed to dose fractionation or tumor targetting.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Although they differ only slightly from each other, the various anthracyclines have their own metabolic pathways and pharmacokinetic parameters. Doxorubicin and daunorubicin have a similar reduced metabolite which reaches low plasma levels in the case of doxorubicin, but is predominant in the case of daunorubicin: daunorubicinol. Aglycones are only formed in large quantities from aclarubicin: aklavinone. The plasma decay of doxorubicin levels is triphasic, with successive half-lives of 5 min, 1 h and 30 h. Unchanged daunorubicin is eliminated more rapidly from plasma, but its metabolite is eliminated more slowly. New anthracyclines such as pirarubicin are characterized by a large volume of distribution, suggesting a higher tissue fixation. These pharmacokinetic data must be kept in mind for the design of new protocols which are aimed to dose fractionation or tumor targetting.
Key concepts: Daunorubicin, Doxorubicin, Pharmacokinetics, Metabolite, Anthracycline, Aclarubicin, Pirarubicin, Pharmacology